140 related articles for article (PubMed ID: 38151408)
21. Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.
Chen J; O'Gorman MT; James LP; Klamerus KJ; Mugundu G; Pithavala YK
Clin Pharmacokinet; 2021 Oct; 60(10):1313-1324. PubMed ID: 33937954
[TBL] [Abstract][Full Text] [Related]
22. Lorlatinib for the treatment of patients with non-small cell lung cancer.
Akamine T; Toyokawa G; Tagawa T; Yamazaki K; Seto T; Takeo S; Mori M
Drugs Today (Barc); 2019 Feb; 55(2):107-116. PubMed ID: 30816885
[TBL] [Abstract][Full Text] [Related]
23. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
24. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Peters S; Shaw AT; Besse B; Felip E; Solomon BJ; Soo RA; Bearz A; Gadgeel SM; Lin CC; Kao S; Seto T; Masters ET; Abbattista A; Clancy JS; Thurm H; Reisman A; Peltz G; Ross Camidge D
Lung Cancer; 2020 Jun; 144():10-19. PubMed ID: 32344248
[TBL] [Abstract][Full Text] [Related]
25. Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
Xie B; Qiu Y; Zhou J; Du D; Ma H; Ji J; Zhu L; Zhang W
Clin Transl Oncol; 2022 Nov; 24(11):2231-2240. PubMed ID: 35852680
[TBL] [Abstract][Full Text] [Related]
26. LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Mori S; Izumi H; Araki M; Liu J; Tanaka Y; Kagawa Y; Sagae Y; Ma B; Isaka Y; Sasakura Y; Kumagai S; Sakae Y; Tanaka K; Shibata Y; Udagawa H; Matsumoto S; Yoh K; Okuno Y; Goto K; Kobayashi SS
Commun Biol; 2024 Apr; 7(1):412. PubMed ID: 38575808
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
Chen J; Houk B; Pithavala YK; Ruiz-Garcia A
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):148-160. PubMed ID: 33449423
[TBL] [Abstract][Full Text] [Related]
28. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece.
Gourzoulidis G; Zisimopoulou O; Liavas A; Tzanetakos C
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):375-385. PubMed ID: 37997764
[TBL] [Abstract][Full Text] [Related]
29. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
Bauer TM; Shaw AT; Johnson ML; Navarro A; Gainor JF; Thurm H; Pithavala YK; Abbattista A; Peltz G; Felip E
Target Oncol; 2020 Feb; 15(1):55-65. PubMed ID: 32060867
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer.
Zhao X; Zhang X; Chen H; Bao H; Wu X; Wang H; Bao H; Pang J; Wang S; Wang J
Clin Chem; 2024 Apr; 70(4):629-641. PubMed ID: 38416709
[TBL] [Abstract][Full Text] [Related]
31. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
Ou SI; Solomon BJ; Shaw AT; Gadgeel SM; Besse B; Soo RA; Abbattista A; Toffalorio F; Wiltshire R; Bearz A
J Thorac Oncol; 2022 Apr; 17(4):568-577. PubMed ID: 35026476
[TBL] [Abstract][Full Text] [Related]
32. First macrocyclic 3
Basit S; Ashraf Z; Lee K; Latif M
Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ; Bauer TM; Mok TSK; Liu G; Mazieres J; de Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
Lancet Respir Med; 2023 Apr; 11(4):354-366. PubMed ID: 36535300
[TBL] [Abstract][Full Text] [Related]
34. An update on lorlatinib: a novel first line treatment for
Riudavets M; Planchard D
Expert Opin Pharmacother; 2023 Feb; 24(3):291-299. PubMed ID: 36542835
[TBL] [Abstract][Full Text] [Related]
35. [Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib].
Zhou Q; Lu S; Li Y; Jia F; Li G; Hong Z; Lu Y; Fan Y; Zhou J; Liu Z; Li J; Wu YL; ;
Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):555-566. PubMed ID: 36002192
[TBL] [Abstract][Full Text] [Related]
36. The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
Nilsson FOL; Asanin ST; Masters ET; Iadeluca L; Almond C; Cooper M; Smith S
Pharmacoeconomics; 2021 Aug; 39(8):941-952. PubMed ID: 34080140
[TBL] [Abstract][Full Text] [Related]
37. Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
Jin C; He Z; Guo M; Liu S; Wang Y; Qiu J; Li C; Wu D
Anticancer Drugs; 2022 Aug; 33(7):696-700. PubMed ID: 35324529
[TBL] [Abstract][Full Text] [Related]
38. Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.
Murakami Y; Kawashima Y; Chiba S; Hara S; Yamazaki Y; Doman T; Saito S; Odaka T; Ogasawara T; Shimizu H; Sugisaka J; Aiba T; Toi Y; Yamanda S; Kimura Y; Sugawara S
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1981. PubMed ID: 38212894
[TBL] [Abstract][Full Text] [Related]
39. Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.
Rupp M; Fanton-Aita F; Snow S; Wheatley-Price P; Melosky B; Juergens RA; Chu Q; Blais N; Banerji S; Ng R; Khoudigian S; Sharma A; On PV; Liu G
Curr Oncol; 2023 Jul; 30(7):6559-6574. PubMed ID: 37504341
[TBL] [Abstract][Full Text] [Related]
40. Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2.
Liao Y; Remsing Rix LL; Li X; Fang B; Izumi V; Welsh EA; Monastyrskyi A; Haura EB; Koomen JM; Doebele RC; Rix U
Cell Chem Biol; 2024 Feb; 31(2):284-297.e10. PubMed ID: 37848034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]